Latigo Biotherapeutics

Website

Latigo Biotherapeutics, Inc.

7 Investors
Biotechnology
THOUSAND OAKS, CA

Latigo Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of non-opioid pain medicines. Based in Thousand Oaks, CA, the company leverages advanced technologies, including artificial intelligence and machine learning, to create innovative treatments that address the unmet needs in pain management.

Products & Team

LTG-001

PharmaceuticalsSeed

LTG-001 is Latigo Biotherapeutics' lead candidate that aims to provide effective non-opioid pain relief. Successfully navigating Phase 1 clinical trials, it addresses the root causes of pain without the associated risks of addiction linked to opioid medications.

Value Proposition

LTG-001 solves the critical problem of finding effective pain treatment for patients at risk of opioid dependency, providing a safer alternative with fewer side effects.

Pain Points

The need for effective pain relief without the high risks of addiction associated with opioids and the gastrointestinal issues stemming from NSAIDs.

Targets fundamental mechanisms of pain transductionEnsures rapid onset of actionSuperior safety profileMinimal central nervous system effectsValidated by human genetics

Tim Lugo

Company Signatory
Chief Financial Officerat Latigo Biotherapeutics, Inc.
Joined Latigo Biotherapeutics, Inc.
February 2025
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
THOUSAND OAKS, CA
Primary headquarters

Funding History

Total Raised:
$50.0M
E

Equity Offering

January 2025
$150.0M
Target
Progress
33%
Raised
$50.0M
Target
$150.0M
#000205661125000001